Liver Supplement

Verify with FDA CVM →

116 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
116
Total Reports
9
Deaths Reported
780.0%
Death Rate

Active Ingredients

Liver Supplement

Administration Routes

OralUnknownOther

Species Affected

Dog 106
Cat 9
Horse 1

Most Affected Breeds

Retriever - Labrador 10
Chihuahua 7
Dog (unknown) 7
Crossbred Canine/dog 7
Terrier (unspecified) 6
Shepherd Dog - German 5
Domestic Shorthair 4
Spaniel - Springer English 4
Spitz - German Pomeranian 3
Poodle - Toy 3

Most Reported Reactions

Vomiting 23
Diarrhoea 22
Elevated alanine aminotransferase (ALT) 19
Lethargy (see also Central nervous system depression in Neurological) 16
Not eating 13
Lack of efficacy - NOS 11
Behavioural disorder NOS 11
Weight loss 10
Decreased appetite 10
Elevated gamma-glutamyl transferase (GGT) 10
Emesis 9
Lethargy (see also Central nervous system depression in 'Neurological') 9

Outcome Breakdown

Outcome Unknown
42 (35.9%)
Ongoing
34 (29.1%)
Recovered/Normal
28 (23.9%)
Euthanized
7 (6.0%)
Recovered with Sequela
4 (3.4%)
Died
2 (1.7%)

Data Summary

Metric Value
Total adverse event reports 116
Reports involving death 9
Case-fatality rate (reported events) 780.0%
Distinct species in reports 3
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Liver Supplement Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 116 adverse event reports referencing Liver Supplement, including 9 reports in which the animal died — a 780.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Liver Supplement. Reported administration routes include Oral, Unknown, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Liver Supplement reports are Dog (106 reports), Cat (9 reports), Horse (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (10), Chihuahua (7), Dog (unknown) (7) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Liver Supplement are Vomiting (23), Diarrhoea (22), Elevated alanine aminotransferase (ALT) (19), Lethargy (see also Central nervous system depression in Neurological) (16). Of the 117 reports with a coded outcome, Outcome Unknown is the leading category at 35.9%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Liver Supplement.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial